Therapeutic Targeting of IL-4- and IL-13-Responsive Cells in Pulmonary Fibrosis
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Immunologic Research
- Vol. 30 (3) , 339-350
Abstract
Severe forms of idiopathic interstitial pneumonia (IIP), such as usual interstitial pneumonia (UIP), can be impervious to modern steroid and immunosuppressive treatment regimens, thereby emphasizing the need for novel effective therapies. Understanding the cytokine networks that may affect immune and structural cell activation and, hence, the progression of these fatal fibrotic diseases, has been a focus in our research. In this regard, we have examined the role of interleukin (IL)-4 and IL-13 and their respective receptor subunits in this process. Examination of clinical surgical lung biopsies (SLBs) showed that IIP is characterized by the abnormal, heightened expression of the receptor subunits that bind IL-4 and IL-13. Specifically, IL-4Rα and IL-13Rα2 (the high-affinity IL-13 receptor subunit) was present in greater abundance in SLBs and fibroblasts from IIP patients compared with normal patients, who exhibited no evidence of pulmonary fibrosis. These clinical findings prompted us to investigate whether the targeting of pulmonary cell types that were highly responsive to IL-4 and IL-13 was a viable therapeutic option in IIP. Using a chimeric protein comprised of human IL-13 and a truncated version of an exotoxin from Pseudomonas (abbreviated IL13-PE), we observed that IL13-PE selectively targeted human pulmonary fibroblasts grown from IIP SLBs, whereas it had a minimal effect on fibroblasts grown from biopsies from normal patients. In murine models characterized by abnormal airway or interstitial fibrotic responses, the intranasal administration of IL13-PE significantly attenuated the fibrotic response through the targeting of IL-4Rα-and IL-13Rα2-expressing pulmonary cells, including monocytes, macrophages, and pulmonary fibroblasts. Together, these data demonstrate that IL-4 and IL-13 are required for the initiation and maintenance of pulmonary fibrosis, and highlight the importance of further investigation of anti-fibrotic therapeutics that prevent the action of both cytokines during clinical pulmonary fibrosis.Keywords
This publication has 63 references indexed in Scilit:
- Does interferon‐γ improve pulmonary function in idiopathic pulmonary fibrosis?European Respiratory Journal, 2003
- Enhanced Interleukin (IL)-13 Responses in Mice Lacking IL-13 Receptor α 2Journal of Experimental Medicine, 2003
- Regulation and Function of the Interleukin 13 Receptor α 2 During a T Helper Cell Type 2–dominant Immune ResponseJournal of Experimental Medicine, 2003
- Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survivalThe American Journal of Medicine, 2001
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 1999
- Novel roles for chemokines and fibroblasts in interstitial fibrosisKidney International, 1998
- Structure of IL-13 Receptor: Analysis of Subunit Composition in Cancer and Immune CellsBiochemical and Biophysical Research Communications, 1997
- IL-4 Upregulates Tenascin Synthesis in Scleroderma and Healthy Skin FibroblastsJournal of Investigative Dermatology, 1996
- Molecular Mechanisms of Antifibrotic Effect of Interferon Gamma in Bleomycin-Mouse Model of Lung Fibrosis: Downregulation of TGF-β and Procollagen I and III Gene ExpressionExperimental Lung Research, 1995
- Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122.Journal of Clinical Investigation, 1991